Group Launches Data-Analytics Contest For Health Providers.

 Exerpt from: DIA Daily enewsletter featuring summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. Subscribe to the DIA Daily.
 

Modern Healthcare (4/18, Conn, Subscription Publication) reports, "There are $300,000 in prizes up for grabs in a new, two-year healthcare data-analytics contest, but first, the sponsors of the competition want healthcare providers and others to identify their knottiest data difficulties so future contestants will have some meaningful problems to solve. 'Today, we call on the entire healthcare community-particularly those serving on the front lines in providing care-to submit the most difficult data challenges facing their organizations as they implement new models of care,' said Dr. Richard Merkin, president and CEO of contest co-sponsor Heritage Provider Network" in a press statement (pdf). The Marina del Rey, California-based "independent practice association, along with the Advisory Board, a healthcare consultancy, and the Bipartisan Policy Center, a Washington-based policy advocacy organization, are co-sponsors of what's being dubbed as the Care Transformation Prize Series."

Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.

Speak at the EuroMeeting 2014

 

26th Annual EuroMeeting 2014
March 25-27 | Vienna, Austria
Abstract submission deadline: May 29

Submit your presentation, session or tutorial abstracts for DIA’s Annual EuroMeeting and share your research with more than 3,000 professionals from around the world.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and manage the session. PowerPoint presentations are required. We welcome innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area. The abstract author is considered the speaker and a PowerPoint presentation is required.

Tutorial Abstract
A tutorial is a ‘hands-on’, interactive learning experience. A tutorial consists of three hours of instruction with a 30-minute break halfway through. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organization as the author.

To give your session, presentation or tutorial abstract the best chance of being accepted focus on the programme themes.

Hot-Topic/Stand-Alone Sessions
Each year, there are a number of sessions that do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes/topics outlined, you may submit it for consideration as a hot-topic/stand-alone presentation/session.

Find Out More | Submit Your Abstract

Sign up for DIA's Global SmartBrief: Break through the information clutter with FREE, twice-weekly email publication that gives quick, easy-to-read summaries of articles relevant to you. Get the latest news in drug development innovations worldwide wherever you are on your laptop or smart phone with SmartBrief’s wireless compatibility.

PCORI needs your help: launching ad hoc workgroups on March 1 -seek input from the healthcare community

February 27, 2013

The Patient-Centered Outcomes Research Institute (PCORI) needs your help as we launch a series of ad hoc workgroups on March 1 to seek input from the healthcare community on refining our initial set of targeted research topics for funding. The workgroups, made up of researchers, patients, and other stakeholders, will meet one time each in March and April. They will provide input to our staff and Board of Governors on the critical research questions that should be answered within each of the five topics, which are: Treatment Options for Severe Asthma in African-Americans and Hispanics/Latinos - March 1 Treatment Options for Uterine Fibroids - March 5 Preventing Injuries from Falls in the Elderly - March 12 Treatment Options for Back Pain - March 21 Obesity Treatment Options in Diverse Populations - April 16 Each workgroup's proceedings will be open to the public via webinar/teleconference. We welcome your comments and suggested research questions via email (targetedPFAworkgroup@pcori.org) and Twitter (@PCORI). We also welcome comments, suggestions, and input from interested individuals for up to two weeks before and after each meeting through our website. You'll find a full list of workgroup meetings and information on how submit input and register for their associated webinars on our site's events page. Our Board approved the development of five targeted funding announcements at its November 2012 meeting. Three topics were identified at that time and two more were identified in January. This accelerated approach to the development of targeted funding announcements will jump-start our long-term strategy to generate and prioritize specific research topics, starting with questions solicited directly from patients and stakeholders. We hope you take the opportunity to participate in one of our workgroup meetings. Your input is critical to our mission to help people make informed health care decisions, and improve health outcomes.

IOM Report Calls For Tracking System To Fight Counterfeit Drug Trade.

The AP (2/14, Neergaard) reports that the Institute of Medicine on Wednesday released a report that concludes, tackling the "problem of fake drugs will require creating a national drug-tracking system." The IOM's report calling "for putting medications through a chain of custody like US courts require for evidence in a trial comes a week after the Food and Drug Administration warned doctors, for the third time in about a year, that it discovered a counterfeit batch of the cancer drug Avastin [bevacizumab] that lacked the real tumor-killing ingredient."

        NPR (2/13, Knox) in its "Shots" blog reports that the "National Academies of Science, of which the IOM is part, was commissioned by the Food and Drug Administration to look at how to protect people against fake and substandard drugs." According to the report, the problem "extends to more than 120 countries...and has done incalculable damage to efforts to control tuberculosis, malaria, AIDS and other diseases."

        The Wall Street Journal (2/14) "Corporate Intelligence" notes that the IOM report also emphasized that oversight of prescription drug wholesalers needs to be strengthened.

        AFP (2/14, Santini) adds that FDA Commissioner Dr. Margaret Hamburg "commended the report" and the agency is already implementing many of its suggestions. "To meet the challenges of today's global marketplace, the FDA is transforming from a predominantly domestically focused agency to one that is fully prepared to help ensure product safety and quality within a globalized world," Dr. Hamburg said in a statement.

        However, according to The Hill (2/14, Wilson) "Regwatch" blog, "Members of Congress want to create legislation to increase the crackdown and oversight effort." Rep. Henry Waxman (R-CA), the "ranking member of the House Energy and Commerce Committee" said "I hope we can pass a law at the federal level that provides the same level of protection as California's model legislation," which requires "individual units of drugs to be accounted for at each step along the supply chain."

        Modern Healthcare (2/13, Zigmond, Subscription Publication), HealthDay (2/14, Gardner) and MedPage Today (2/14, Pittman) also cover the reports, which is titled, "Countering the Problem of Falsified and Substandard Drugs."

from DIA Daily

DIA Daily. This daily enewsletter features summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. This easy-to-read enewsletter is delivered to your inbox every business morning.

Subscribe to the DIA Daily.
View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Sciences - Boston, June 23-27

About DIA 2013 DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Sciences is the largest multidisciplinary event that brings together a global network of professionals to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

DIA 2013 49th Annual Meeting will:

• Provide a global unbiased platform to raise the level of discussion to facilitate innovation that will change the future of health care
• Provide comprehensive coverage of the full development and life cycle management process for all health care products
• Offer a holistic and integrated approach to the development and life cycle management of regulated health care products

To that end, DIA 2013 49th Annual Meeting provides the best opportunity to meet with people from around the world, share your views and knowledge, network, and build new relationships.

---

“A lot is being done to try to advance clinical development to become more efficient, to become more effective, and that the DIA provides an opportunity to share those kinds of ideas.” - Jeffrey McMullen, President and CEO, PharmaNet/i3

“Well, DIA really prides itself on providing a neutral forum. And that aspect of neutrality not only means that our attendees can have more confidence in the content, but it also means we have a lot more diversity of stakeholders presenting.” - Craig Lipset, DIA 2012 Program Chair

“It’s definitely one of the leading meetings that we attend.” - Josef von Rickenbach, Chairman and CEO, PAREXEL International

---

DIA’s Annual Meeting brings together all the stakeholders to enhance the health and well-being of patients.

Special Opportunities for Patient Representatives - Deadline for application is Feb. 1

Special Opportunities for Patient Representatives Dear Colleague, Do you represent a 501(c)(3) organization in the United States or registered charities in Canada that serve constituents with major chronic diseases and/or rare/orphan diseases? Then you can’t afford to miss your opportunity to apply for a scholarship to attend the DIA 2013 49th Annual Meeting as part of the Patient Advocate Fellowship Program. Through the Patient Advocate Fellowship Program, DIA is working to ensure that the "voice of the patient" is heard globally in every facet of the life cycle management of pharmaceuticals, medical devices, and related health care products. Twenty patient representatives, chosen through a competitive process, will have opportunities to develop, strengthen, and support collaborations with policymakers, industry, academia, and health professionals by taking part in all facets of DIA 2013 49th Annual Meeting in Boston. Deadline for Applications: Friday, February 1 What is the Patient Advocate Fellowship Program? The DIA Patient Advocate Fellowship Program is designed to: • Develop, strengthen, and support patient collaborations with policy makers, health professionals, industry representatives, and academia • Increase the knowledge and understanding of patient groups about key issues central to patient-centered health care, biomedical research, and drug development • Develop the capacity of patient groups to advocate for change • Improve alliances between patient groups and other health care stakeholders • Stimulate cooperation, promote dialogue, and share best practices Hear more about DIA's Patient Advocate Fellowship Pogram: DIA 2012 48th Annual Meeting Participating Organizations: • ARPKD/CHF Alliance • Averys Angels Gastroschisis Foundation • Canadian Organization for Rare Disorders • Cholangiocarcinoma Foundation • HepTREC • Huntington's Disease Society of America • International Cancer Advocacy Network • International WAGR Syndrome Association • Lupus Foundation of America • Mass General Cancer Center • Mastocytosis Society • MRSA Survivors Network • National Alliance for Medication Assisted Recovery • National Dysautonomia Research Foundation • Nueva Vida (Latin Women with Cancer) • Ovarian Cancer National Alliance • Soft Bones • Sturge-Weber Foundation • United Nations Bone and Joint Decade • Vestibular Disorders Association What is the DIA 2013 49th Annual Meeting? DIA 2013 49th Annual Meeting connects all partners involved in bringing new therapies to patients. Historically, this enterprise has focused on drug development, but today those partners include a very diverse range of stakeholders from biotechnology, diagnostics, and medical device companies, to regulatory agencies, scientific and academic communities, service payers and providers, and patient organizations. See for Yourself What Others Say about the DIA Annual Meeting... Global Patient Initiatives Patient organizations are key stakeholders in DIA’s mission to foster innovation to improve health and well-being worldwide. Find out how you can make an impact as a patient group representative. Questions About the Application or Eligibility? Contact Donna Mayer at Donna.Mayer@diahome.org. Special Discount for Patient Organizations: DIA offers another opportunity for patient organizations at the Annual Meeting by offering registration for only $250, which includes a one-year complimentary e-membership. Proof of 501 (c)(3) status required. Download the registration form. Keynote Speaker: Daniel Kraft, MD Executive Director, FutureMed Hear from Dr. Kraft regarding the DIA 2013 49th Annual Meeting

Email Preferences | My DIA | Forward to a Friend |

A new model of surgery for 2030: De-skilled, decentralized and device-driven

What’s the vision of medical device firms as they innovate for a new model of care, not just in the U.S. but globally?

What they see, according to a new report, is a two-tiered healthcare system that’s demanding more sophisticated, efficient devices for surgeries and, at the same time, more simple devices that can be used by patients, or “consumers.” Technology design and development firm Cambridge Consultants hosted a workshop with participants from companies like Covidien, Boston Scientific, C.R. Bard, Philips Healthcare and Harvard Medical School, and compiled their insight into a report that lays out the landscape for surgery in 2030.

A few major insights emerged from the workshop, the first being that frontline care organizations will consolidate and create international “mega hospitals.” A pickup in hospital M&A activity over the last few years shows we’re already headed in that direction. With that, care organizations will shift toward a common model of care and management, and result in a robust set of industry best practices.

Low-risk surgical procedures, and the tools needed to perform them, will increasingly be designed to be carried out in physicians’ offices or drop-in clinics, reserving use of high-cost infrastructure only for the most serious of procedures that require those resources — something we’re already seeing in gynecology and urology. Many patients will then recover at home with the use of monitoring devices.
For medical device makers, this means the move toward vertical integration, or “ownership of a disease.” They’ll also need to learn how to serve customers and not just treat patients as two-tier health systems develop, the report proposes.


Read more: http://medcitynews.com/2013/01/a-new-model-of-surgery-for-2030-deskilled-decentralized-and-device-driven/#ixzz2IKlyTgkG

PCORI approves 25 awards, totaling $40.7 million over three years, to fund patient-centered CER

December 18, 2012

The Patient-Centered Outcomes Research Institute (PCORI) has approved its first primary research projects. PCORI today announced the approval of 25 awards, totaling $40.7 million over three years, to fund patient-centered comparative clinical effectiveness research projects under the first four areas of its National Priorities for Research and Research Agenda.

All proposals were approved by PCORI's Board of Governors pending a business and programmatic review by PCORI staff and completion of a formal award contract.   The approved research projects, based at institutions in 17 states, resulted from PCORI's first cycle of primary research funding announcements issued May 22. PCORI received nearly 500 applications. The approved projects were selected through a competitive, multi-stage review process that incorporated patients, caregivers and other stakeholders in the evaluation of proposals. Applications were evaluated on scientific merit, engagement of patients and other stakeholders, methodological rigor and fit within PCORI's research priorities and research agenda.   The projects approved for funding include those that will study ways to improve care for people with such health problems as bacterial and viral infections, cardiovascular disease and stroke, certain cancers, chronic kidney disease, chronic pain, depression and other serious mental illness, and pediatric diabetes, as well cross-cutting proposals investigating how to improve care for people with multiple conditions. Other projects seek ways to improve patient-clinician communication, reduce selected health disparities, and improve the way healthcare systems operate.   Information on all of today's awards, including the project name, primary investigator, and research institution, is provided on the PCORI website, www.pcori.org.   For more information about PCORI funding opportunities visit www.pcori.org/funding-opportunities.   #####

About PCORI The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed health care decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work.

IRS Finalizes ACA's Medical Device Tax Rule.

Reuters (12/6, Temple-West) reports that the Internal Revenue Service on Wednesday released a final rule (pdf) on medical-device taxes, under which manufacturers will have to pay a 2.3 percent tax on their gross sales, starting in January, unless industry groups succeed with their calls, urging Congress to repeal it. The tax is projected to generate $29 billion to help fund the Affordable Care Act through 2022. Reuters quotes IRS spokesperson Sabrina Siddiqui as saying, "The excise tax is on the medical device manufacturers and importers (who) will now have access to 30 million new customers due to the healthcare law."

        CQ (12/6, Adams, Subscription Publication) notes that although the "58-page final rule" explains "which types of manufacturers will face the excise tax and filing requirements," the bulk of the document is "devoted to responding to comments from manufacturers and others about which products are subject to the tax and under what conditions." Unless Congress acts to change it, the rule mandates that medical-device manufacturers must "start sending in semimonthly tax payments starting Jan. 29." CQ adds that the release of the rule sparked renewed outcries from industry groups. For example, Advanced Medical Technology Association CEO Stephen Ubl issued a statement saying, "While Washington talks about a fiscal cliff, this tax could push us off an innovation cliff, costing as many as 43,000 jobs and hurting the ability of medical technology companies to find tomorrow's treatments and cures." The rule "should be repealed," Ubl added.

        Modern Healthcare (12/6, Lee, Subscription Publication) adds that the Medical Imaging and Technology Alliance "urged lawmakers to pass legislation that would delay implementation of the excise tax." Its Executive Director Gail Rodriguez issued a statement saying, "MITA strongly urges Congress to enact legislation immediately to delay implementation of the medical device tax." She stressed that, "ultimately, Congress should repeal this job-killing tax."

DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191

Latin America: get the latest clinical information, knowledge resources and regulatory news in the life sciences and health care industry with DIA electronic membership

Electronic Membership now available in Latin America! Dear Colleague, You asked, we delivered! It is my pleasure to invite you to join DIA as a Member.  DIA’s electronic Membership provides with online tools and digital access to an outstanding collection of tools and resources to keep you ahead of the curve on the latest clinical information, knowledge resources and regulatory news in the life sciences and health care industry – all for just $35 a year. SAVE THE DATES In addition, as part of your membership you have access to all the below tools and resources. To register online, click here or to download a form, click here. Enter your country and choose eMembership from the dropdown list. eMembers-only registration discounts on DIA Latin America conferences and over 200  DIA offerings across the globe and online New! Members-only free archived webinars. Take advantage of a hot topic webinar as a complimentary member benefit – without leaving your desk New! DIA Online Member Directory. Network locally and globally, share documents and discussions, connect with colleagues and create your own network of colleagues and industry thought leaders. Digital Subscription (6 issues each) to: New in 2013! Subscription to Therapeutic Innovation & Regulatory Science publication, DIA’s peer-reviewed, scholarly journal (formerly the Drug Information Journal) Global Forum – your association digital news magazine featuring practical tips, regulatory and global industry updates Online Communities and DIA ConneX: Members-only professional networking platform and Special Interest Area Communities (SIACs) – DIA’s discipline specific groups that share best practices and the latest information related to your field DIA Online Career Center– your source to find and list employment opportunities If you have any questions regarding membership or joining, please contact us at membership@diahome.org. Sincerely, Alejandro Bermudez-Del-Villar, MA/IBBD Latin America & Global Program Development Coordinator Alejandro.Bermudez@diahome.org

Patient Safety: A Sustained Focus from Scientific Ideas to Innovative Medicines - 5th DIA China Annual Meeting - May 12-15, 2013 - Beijing

Hot Topics and Sessions at 5th DIA China 2013 Annual Meeting This year’s theme “Patient Safety: A Sustained Focus from Scientific Ideas to Innovative Medicines”  will reinforce patient safety as a core element of therapeutic innovation and a key philosophy throughout the life cycle of biopharmaceutical R&D. 5th DIA China 2013 Annual Meeting will be held on May 12-15, 2013 at the Beijing International Convention Center in Beijing. It is expected to attract over 1200 professional participants, spotlighted with plenary and parallel sessions, including pre-conference workshops, forums, speakers and presentations, panel discussions, call for abstracts & posters, exhibitions, networking receptions, and more. 5th DIA China 2013 Annual Meeting is the largest annual meeting held by DIA in Asia & Pacific region, providing a neutral platform for information exchange, featuring speakers that include high-level representatives from government, industry and academics in China and abroad. In 2012, the 4th DIA China Annual Meeting attracted over 1170 participants from all sectors, including multi-national pharma, local pharma, CRO, bio-pharma, regulatory agencies, academic institutes, and clinical sites. NEW subject matter and hot topics include: China drug safety monitoring system and update Medical devices and combinational drugs Oncology drug research - demands and challenges Over the counter drug development in China Pharmacoepidemiology Risk benefits Traditional Chinese Medicines - regulations and patient benefits Don’t miss the region’s biggest meeting for pharmaceutical and medical product professionals to seek the most-up-to-date information and innovative tools you need to get ahead, especially within patients and their safety. DIA China cordially invites you to join us for the 5th DIA China 2013 Annual Meeting! Co-Sponsored By:  China Center for Pharmaceutical International Exchange (CCPIE) CONTACT INFORMATION Conference: Runshan CHEN: ting.chen@diachina.org Fei XIE: fei.xie@diachina.org Tel: +86.10.6260.2240 Exhibtion, advertisement, hosting: Jean XU: jxu@kellencompany.com Tel: +86.10.5923.1096 Sofie PEETERS: speeters@kellencompany.com Tel: +86.159.1093.4696 DIA中国办公室 (DIA CHINA OFFICE) 中国北京海淀区中关村西区海淀东三街2号，欧美汇大厦七层766室，邮编100080 7/F, Room 766, Metropolis Tower, No.2 Haidian East Third Street, Zhongguancun Xi Zone, Haidian District, Beijing, 100080, China Tel: +86.10.6260.2240         Fax: +86.10.6260.2201 Email: dia@diachina.org        Web: www.diachina.org

New Combinations to Fight Cancer

Data from experiments using 5,000 different pairings of approved drugs will be made available.

Researchers at the National Cancer Institute have tested 5,000 different combinations of 100 approved cancer drugs in the hope of finding new pairings that could ultimately provide patients with more effective and safer treatments.

Scientists in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute completed some 300,000 experiments aimed at testing all possible combinations of every currently approved small molecule cancer drug in the United States.

continue:
http://www.burrillreport.com/article-new_combinations_to_fight_cancer.html

IOM estimates suggest that as much as 750 billion dollars is spent every year within the US health system without contributing to better health

Global Health blog: Health Technology Assessment in the Americas

from Center for Global Development - Latest Updates by cgdev.rss@cgdev.org (CGD RSS feed)

By Amanda Glassman - This is a joint post with Kate McQueston.
“Every country, no matter how wealthy or how impoverished, cannot afford to waste money in healthcare on health technology that does not contribute to health.”

These words were spoken by Harvey V. Fineberg, the President of the Institute of Medicine, at a recent event co-hosted by CGD and PAHO, which highlighted the importance of supporting health technology assessment (HTA) in the Americas. Low-and middle-income countries are increasingly interested in building capacity for priority setting, particularly in regards to public funding in a time where pressures to incorporate costly new technologies are on the rise and donor contributions are stagnating. Over the past five years Brazil, Chile, Costa Rica, Colombia, Croatia, Estonia, the Republic of Korea, Malaysia, and Uruguay have also added health technology assessment agencies—tasked with varying responsibilities, including the generation or coordination of health technology assessment and budget impact analysis, as well as the creation recommendations for coverage or reimbursement decisions related to public spending.

Of his main key points, Dr. Fineberg pointed out that recent IOM estimates suggest that as much as 750 billion dollars is spent every year within the US health system without contributing to better health...

please see full article...

Columnist Discusses Impact Of Election On FDA.

In Pharmalot (11/6), columnist Ed Silverman discusses how the outcome of the upcoming election will impact the FDA. Steve Grossman of the Alliance For A Stronger FDA non-profit, says that the FDA is not part of the election campaign dialogue. Grossman says this is a good thing, since "any intelligent discussion requires a long-term perspective and a mastery of detail and nuance, both of which are in short supply during sound bite-oriented politicking." However, he notes that the FDA will ultimately be affected by the election. Silverman asserts that the notion that the FDA "would largely continue on its current path with an Obama re-election is not hard to imagine. ... With Romney in the White House, however, the agency is likely to look and feel quite differently – and have a commish who is willing to 'swing the pendulum' away from an emphasis on safety and take any number of steps to speed approvals, regardless of budget cuts."

 

DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org. Click here to check your membership status.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044

Copyright © 2012 by BulletinHealthcare | 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191